About Oncoheroes
Oncoheroes is a Healthcare company based in Brookline (United States) founded in 2017 by Cesare Spadoni, Marc Goldberg, and Marco Munoz. It operates as a therapies for pediatric cancer in children are discovered and developed. Oncoheroes has raised $9.95 million across 2 funding rounds from investors including Dreamers Ventures. Oncoheroes offers products and services including Drug Discovery, Clinical Development, and Community Partnering. Its focus areas include Life Sciences, Oncology, Drugs and Pediatric Cancer. Its legal entity is Oncoheroes Biosciences Inc. Its competitors include Ironwood Pharma, VeraDermics, VISEN Pharmaceuticals, Castle Creek Biosciences and Proveca and 4 more; 7 of its 9 listed competitors have raised funding.
Company details
Oncoheroes was founded in 2017 in Brookline, United States, within the biotechnology sector. Focus is placed on the discovery and development of oncology drugs targeted at children and adolescents with cancer. The product pipeline encompasses Volasertib for alveolar rhabdomyosarcoma, Dovitinib for osteosarcoma, and Stenoparib for various pediatric solid tumors including neuroblastoma, sarcomas, and central nervous system tumors. Operations are centered on advancing these therapies through clinical stages.
- Headquarters Brookline, United States
- Founders Cesare Spadoni, Marc Goldberg, Marco Munoz
- SectorsHealthcare
- Email••••••••
- Website oncoheroes.com
- Social LinkedIn X Facebook Instagram
- Legal Name Oncoheroes Biosciences Inc.
- Total Equity Funding$9.95M (USD)
in 2 rounds
- Latest Funding Round$1.1M (USD), Series A
Mar 2020
- Investors
Products & Services of Oncoheroes
Oncoheroes offers a comprehensive portfolio of products and services, including Drug Discovery, Clinical Development, and Community Partnering.
Identifies precision targets for novel drug combinations in pediatric cancers.
In-licenses assets to advance potential cures for childhood cancers.
Partners with industries and foundations for therapy development support.
Funding Insights of Oncoheroes
Oncoheroes has successfully raised a total of $9.95M across 2 strategic funding rounds. The most recent funding activity was a Series A round of $1.1 million completed in March 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $9.95M
- Total Rounds 2
- Last Round Series A — $1.1M
- First Round $8.85M
(Feb 2018)
- Investors Count 1
All 2 funding rounds of Oncoheroes with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar 2020 | $1.1M | Series A | – | Dreamers Ventures | – |
| Feb 2018 | $8.85M | Series A | – | – | – |
1 investors in total: 1 institutional.
Investors in Oncoheroes
Oncoheroes has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include Dreamers Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
- | – | dreamers-vc.com | - |
Investor details for Oncoheroes
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Oncoheroes
20 people are tracked at Oncoheroes (5 in leadership, 14 in board & advisors, 1 in team).
| Name | Role | Group |
|---|---|---|
Cesare Spadoni | Co-Founder & COO | Leadership |
Marc Goldberg | Co-Founder | Leadership |
Marco Munoz | Co-Founder | Leadership |
Ricardo García | Founder I CEO | Leadership |
Edward Garmey | Consultant CMO | Leadership |
Marta Príncep | Strategic Advisor | Board & advisors |
Gonzalo García | Strategic Advisor | Board & advisors |
Marco Muñoz | Founder & Board Member | Board & advisors |
Franklin Salisbury, Jr. | Board Member | Board & advisors |
Steven Dubois | Scientific Advisor | Board & advisors |
Tomás Tomeo Foncuberta | Strategic Advisor | Board & advisors |
Antonio Sanchez-Cordero | Strategic Advisor | Board & advisors |
Dean Crowe | Strategic Advisor | Board & advisors |
Jaroslav Sterba | Scientific Advisor | Board & advisors |
Kirk G. Tanner | Senior Advisor | Board & advisors |
Peter Adamson | Scientific Advisor | Board & advisors |
Juliet Gray | Scientific Advisor | Board & advisors |
Lee J. Helman | Scientific Advisor | Board & advisors |
Daniel Morgenstern | Scientific Advisor | Board & advisors |
Evgenia Mengou | Regulatory Affairs Advisor | Team |
Complete people profiles for Oncoheroes
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Oncoheroes
3 dated milestones of Oncoheroes across 3 years, from founding to its latest funding, stage changes and deals.
- Founded Oncoheroes is founded.
- Funding First funding round of $8.9M.
- Funding Latest funding round, Series A, of $1.1M.
Competitors of Oncoheroes
Oncoheroes has 9 listed competitors in our database, 7 of them funded. They include Ironwood Pharma, VeraDermics, VISEN Pharmaceuticals, Castle Creek Biosciences and Proveca, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| ironwoodpharma.com | 1998 | Cambridge, United States | $206.25M | 220 | Therapeutics for gastrointestinal disorders, including linaclotide, are developed. | |
| veradermics.com | 2020 | San Antonio, United States | $262.71M | – | Drug-delivery platforms for pediatric wart treatments are developed. | |
| visenpharma.com | 2018 | Shanghai, China | $150M | 3 | Therapeutics for endocrine diseases are developed using TransCon technology. | |
| castlecreekbio.com | 2018 | Exton, United States | $192.8M | 41 | Gene therapy platform for rare disease treatments is developed. | |
| proveca.com | 2010 | Manchester, United Kingdom | $8.45M | 23 | Medicines for chronic diseases in children are developed and provided. | |
| lipum.se | 2010 | Umea, Sweden | $2.99M | – | Developer of antibody to treat juvenile idiopathic arthritis | |
| orphelia-pharma.eu | 2007 | Paris, France | $4.49M | – | Therapies for pediatric neurology, oncology, and hematology are developed. | |
| allievex.com | 2017 | Marblehead, United States | – | 7 | Developer of therapeutics for rare neurodegenrative diseases | |
| gate2brain.com | 2019 | Barcelona, Spain | – | – | Therapeutics delivery platform across biological barriers is developed. |
Detailed competitors of Oncoheroes
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Pediatrics
10 companies that operate in the same segment as Oncoheroes (Pediatrics), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Owlet is recognized for developing FDA-cleared smart baby monitors. | 2013 | Lehi, Utah, United States | USD 54.96 M | USD 105.71 M | 85 | |
Therapeutics for gastrointestinal disorders, including linaclotide, are developed. | 1998 | Cambridge, Massachusetts, United States | USD 206.25 M | USD 296.15 M | 253 | |
Smart baby monitors and sleep tracking solutions are provided. | 2014 | New York, New York, United States | USD 116.6 M | – | – | |
Provider of diagnostic products for pediatrics | 2013 | Durham, North Carolina, United States | USD 95.89 M | – | – | |
Eye-tracking solutions for vision assessment and treatment are provided. | 2016 | Lod, Central District, Israel | USD 8 M | – | – | |
Patient vital signs are monitored via wearable devices and software. | 2018 | Niles, Illinois, United States | USD 71 M | – | – | |
Pediatric orthopedic devices are developed for surgical applications. | 2006 | Warsaw, United States | USD 51.55 M | USD 236.35 M | 562 | |
Gene therapy platform for rare disease treatments is developed. | 2018 | Exton, Pennsylvania, United States | USD 192.8 M | – | 41 | |
Pediatric cardiac surgical devices are developed for congenital heart defects. | 2011 | Pittsburgh, Pennsylvania, United States | USD 22.56 M | – | – | |
Drug-delivery platforms for pediatric wart treatments are developed. | 2020 | San Antonio, Texas, United States | USD 262.71 M | – | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Oncoheroes
Complete news archive for Oncoheroes
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Oncoheroes
Oncoheroes was founded in 2017 and raised its 1st funding round 1 year after it was founded.
Oncoheroes is headquartered in Brookline, United States. It is registered at Brookline, Massachusetts, United States.
Oncoheroes is a funded company, having raised a total of $9.95M across 2 funding rounds to date. The company's 1st funding round was a Series A of $8.85M, raised on Feb 2018.
Oncoheroes was founded in 2017 in Brookline, United States, within the biotechnology sector. Focus is placed on the discovery and development of oncology drugs targeted at children and adolescents with cancer. The product pipeline encompasses Volasertib for alveolar rhabdomyosarcoma, Dovitinib for osteosarcoma, and Stenoparib for various pediatric solid tumors including neuroblastoma, sarcomas, and central nervous system tumors. Operations are centered on advancing these therapies through clinical stages.
Oncoheroes's top competitors include Ironwood Pharma, Castle Creek Biosciences and VeraDermics.
Oncoheroes offers Drug Discovery, Clinical Development, and Community Partnering.
Oncoheroes has 1 investor. Key investors include Dreamers Ventures.
Oncoheroes operates through Oncoheroes Biosciences Inc..